ASH 2018 | Progression risk-based classification of smoldering Waldenström’s macroglobulinemia
Irene Ghobrial
• 4 Dec 2018
Smoldering Waldenström’s Macroglobulinemia (SWM) is the ideal stage to treat the disease and prevent progression to Waldenström’s macroglobulinemia (WM). Here, Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the development of a classification system based on the risk of progression from SWM to symptomatic WM. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Ghobrial explains how this will allow the stratification of SWM patients into low-, intermediate- and high-risk groups, allowing the identification of patients who might benefit from early intervention in this rare malignancy.
